Solara Active Pharma Sciences Ltd

Solara Active Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Solara Active Pharma Sciences Ltd

₹ 491 4.94%
21 Feb - close price
solara.co.in BSE: 541540 NSE: SOLARA
About

Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]

It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]

Key Points

Business Segments
It is a global, R&D-focused, pure-play Active Pharmaceutical Ingredients (API) company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies. [1]

Website BSE NSE
  • Market Cap ₹ 2,053 Cr.
  • Current Price ₹ 491
  • High / Low ₹ 886 / 327
  • Stock P/E
  • Book Value ₹ 301
  • Dividend Yield 0.00 %
  • ROCE -8.67 %
  • ROE -33.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Debtor days have improved from 125 to 98.7 days.
  • Company's working capital requirements have reduced from 197 days to 126 days

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -1.45% over past five years.
  • Company has a low return on equity of -11.3% over last 3 years.
  • Promoters have pledged 40.7% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare BSE Allcap BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
100.34 360.82 330.07 338.37 394.75 380.62 352.31 425.24 211.94 299.43 363.49 346.95 300.31
197.18 347.29 317.52 310.80 349.75 331.85 333.19 387.61 373.63 289.67 321.57 285.64 242.63
Operating Profit -96.84 13.53 12.55 27.57 45.00 48.77 19.12 37.63 -161.69 9.76 41.92 61.31 57.68
OPM % -96.51% 3.75% 3.80% 8.15% 11.40% 12.81% 5.43% 8.85% -76.29% 3.26% 11.53% 17.67% 19.21%
3.21 4.76 6.98 3.72 7.17 4.68 2.04 -4.04 -62.32 -120.48 0.56 0.32 1.49
Interest 17.82 21.47 22.50 21.96 23.64 21.96 24.61 24.44 25.37 30.69 30.87 28.28 26.54
Depreciation 28.44 27.82 28.13 28.63 27.98 26.45 25.91 26.21 25.96 25.25 25.07 25.34 24.54
Profit before tax -139.89 -31.00 -31.10 -19.30 0.55 5.04 -29.36 -17.06 -275.34 -166.66 -13.46 8.01 8.09
Tax % 0.00% -105.84% -47.11% -48.29% 21.82% 25.40% -34.91% 0.00% 0.00% 53.28% 0.00% 0.00% 0.00%
-139.89 1.81 -16.45 -9.98 0.43 3.76 -19.11 -17.06 -275.34 -255.45 -13.46 8.01 8.09
EPS in Rs -29.20 0.39 -3.42 -2.08 0.09 0.79 -4.07 -3.58 -57.36 -53.20 -3.74 2.22 2.24
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
521 1,387 1,322 1,617 1,268 1,444 1,289 1,310
464 1,174 1,062 1,231 1,188 1,309 1,384 1,140
Operating Profit 57 213 260 386 81 134 -95 171
OPM % 11% 15% 20% 24% 6% 9% -7% 13%
2 12 27 29 16 22 -185 -118
Interest 25 82 78 84 75 90 105 116
Depreciation 34 83 94 109 112 111 103 100
Profit before tax 0 60 115 222 -91 -45 -488 -164
Tax % -70% 1% 0% 0% -36% -50% 16%
0 59 115 221 -58 -22 -567 -253
EPS in Rs 17.30 32.01 46.22 -12.11 -4.62 -118.21 -52.48
Dividend Payout % 0% 22% 5% 11% 0% -49% 0%
Compounded Sales Growth
10 Years: %
5 Years: -1%
3 Years: -7%
TTM: -4%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 18%
Stock Price CAGR
10 Years: %
5 Years: -5%
3 Years: -9%
1 Year: 9%
Return on Equity
10 Years: %
5 Years: -2%
3 Years: -11%
Last Year: -34%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 25 26 27 36 36 36 36 40
Reserves 739 930 1,059 1,553 1,489 1,464 898 1,046
633 538 722 621 1,037 1,013 1,012 840
425 466 346 404 383 386 406 364
Total Liabilities 1,821 1,960 2,153 2,614 2,945 2,899 2,351 2,290
1,086 1,218 1,397 1,382 1,356 1,364 1,268 1,231
CWIP 71 40 40 88 239 238 256 272
Investments 1 0 0 0 0 2 2 2
663 701 716 1,144 1,350 1,295 825 786
Total Assets 1,821 1,960 2,153 2,614 2,945 2,899 2,351 2,290

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
49 166 242 155 -242 156 109
-85 -113 -359 -106 -243 -81 -4
68 -23 97 92 334 -113 -106
Net Cash Flow 31 30 -20 142 -151 -38 -0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 184 76 63 109 141 136 99
Inventory Days 252 111 170 149 321 258 163
Days Payable 420 127 132 156 154 142 142
Cash Conversion Cycle 16 60 101 102 308 252 120
Working Capital Days 107 34 67 118 251 213 126
ROCE % 10% 12% 15% -0% 2% -9%

Shareholding Pattern

Numbers in percentages

3 Recently
Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
39.71% 40.40% 40.41% 40.41% 40.98% 39.31% 37.19% 30.49% 30.49% 37.27% 37.27% 37.23%
19.42% 17.93% 18.47% 19.26% 19.30% 18.71% 17.86% 16.62% 15.80% 14.00% 14.25% 14.67%
3.64% 3.10% 2.97% 3.01% 2.75% 1.75% 1.79% 1.75% 2.97% 2.83% 3.37% 3.19%
37.22% 38.57% 38.16% 37.32% 36.95% 40.22% 43.16% 51.14% 50.73% 45.89% 45.11% 44.92%
No. of Shareholders 77,22882,71083,31979,14976,32575,41774,47372,91873,91277,17071,88283,148

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls